Industries > Pharma > Global Medical Marijuana Market 2017-2027

Global Medical Marijuana Market 2017-2027

Chronic Pain, Arthritis, Migraine, Cancer, National Markets, Patent Analysis, Leading Companies

PUBLISHED: 22 August 2017
PAGES: 120
PRODUCT CODE: PHA0228
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0228 Categories: , Tag:

The global medical marijuana market was valued at $12bn in 2016 and is projected to grow at a CAGR of 18% in the first half of the forecast period. The market is dominated by the Chronic Pain submarket which held 40% share of that market in 2016.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 120-page report you will receive 87 charts – all unavailable elsewhere.

The 120-page report provides clear detailed insight into the global medical marijuana market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Medical Marijuana Market forecasts from 2017-2027

• Revenue forecast for the medical marijuana market by Application:
• Chronic Pain
• Arthritis
• Migraine
• Cancer
• Others

Each submarket is further divided by region: North America, Europe, RoW

• This report provides individual revenue forecasts to 2027 for these regional and national medical marijuana markets:
• North America:
• USA
• Canada

• Europe:
• Belgium
• Croatia
• Finland
• France
• Italy
• Rest of Europe

• RoW:
• Israel
• Australia
• Other Countries

Global Medical Marijuana Market 2017-2027

• This report discusses the leading companies in the global medical marijuana market:
• Cara Therapeutics, Inc.
• Cannabis Sativa, Inc.
• CannaGrow Holdings, Inc.
• Aphios Corporation
• United Cannabis Corporation
• Growblox Sciences, Inc.
• GreenGro Technologies, Inc.
• GW Pharmaceutical, PLC.
• International Consolidated Companies, Inc.
• Lexaria Biosciences Corp.

• This report also listed 84 other companies involved in medical marijuana production, including their reported revenues (when available) and number of employees

• This report provides a patent analysis table for medical marijuana

• This report discusses the drivers, restraints as well as porter’s five forces analysis of the global medical marijuana market

Visiongain’s study is intended for anyone requiring commercial analyses for the global medical marijuana market. You find data, trends and predictions.

Buy our report today Global Medical Marijuana Market 2017-2027: Chronic Pain, Arthritis, Migraine, Cancer, National Markets, Patent Analysis, Leading Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Medical Marijuana Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Medical Marijuana Market 2017-2027


Latest Pharma news

“The worldwide industry for silicone additives is likely to experience important development”, says Visiongain

It is anticipated that the benefits of silicone additives such as elevated drop, marine strength, and leveling & humidity regulate will boost their use in cosmetics, coatings, and paint applications.

16 October 2019

READ

“Global nephrology and urology devices market is anticipated to surpass USD 39 Bn by 2030”, says Visiongain

Nephrology is a field of medicine that is concerned with studying kidney function, treating kidney issues, and therapy for renal substitute.

16 October 2019

READ

“The global Nasal Drug Delivery Technology market is anticipated to surpass USD 80 Billion by 2030”, says Visiongain

Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the availability of effective treatment methods, high unmet clinical needs, rising disposable income levels, and increasing awareness about these products.

16 October 2019

READ

“The global Myeloproliferative Disorders Drugs market is anticipated to surpass USD 11 Bn by 2030”, says Visiongain

The emergence of a new therapy for myeloproliferative disorders and the accessibility of new drugs is anticipated to drive the market drugs for myeloproliferative disorders.

16 October 2019

READ

Categories

Category